This trial is active, not recruiting.

Condition type 1 diabetes mellitus
Sponsor National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator National Institute of Allergy and Infectious Diseases (NIAID)
Start date September 2004
End date September 2025
Trial size 8668 participants
Trial identifier NCT00279318, 1UC4DK095300-01, 1UC4DK100238-01, 1UC4DK106955-01, DK095300; DK100238; DK106955


The long-term goal of the TEDDY study is the identification of infectious agents, dietary factors, or other environmental agents, including psychosocial factors which trigger T1DM in genetically susceptible individuals or which protect against the disease. Identification of such factors will lead to a better understanding of disease pathogenesis and result in new strategies to prevent, delay or reverse T1DM.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Newborns with high risk HLA in the general population or having a first-degree relative affected with T1DM.

Primary Outcomes

Appearance of one or more islet cell autoantibodies: GADA, IAA, or IA-2A confirmed at two consecutive visits.
time frame: September 2025

Secondary Outcomes

Development of T1DM
time frame: September 2025

Eligibility Criteria

Male or female participants up to 4 months old.

Inclusion Criteria: - Newborns with high risk HLA in the general population or having a first- degree relative affected with T1DM - Newborns are less than 4 months of age Exclusion Criteria: - Have an illness or birth defect that precludes long-term follow-up or involves use of treatment that may alter the natural history of diabetes (e.g. steroids or insulin) - Refuses to have blood and stool samples stored at the NIDDK Repository

Additional Information

Official title Consortium for Identification of Environmental Triggers of Type 1 Diabetes
Principal investigator Jeffrey P. Krischer, PhD
Description Epidemiologic patterns suggest that viruses, nutrition, toxic agents or socioeconomic psychosocial factors may contribute to the etiology alone or in combination. Elucidation is confounded by the long interval between exposure and onset of clinical disease, as well as the interaction of multiple genes and/or insults, which appear to interact in a complex manner. Numerous studies have investigated environmental influences but have yielded conflicting results. This may be in part due to the failure to account for genetic susceptibility, begin observation at early ages or in utero, and/or monitor subjects long term and frequently. Hypotheses: 1. Initiation of persistent beta-cell autoimmunity and progression from beta-cell autoimmunity to diabetes is increased with: 1. Exposure to a trigger factor during pregnancy, such as infections, preeclampsia, blood incompatibility, or birth weight. 2. Differences in the timing of the introduction and/or the type of dietary constituents that include exposure to cereals or gluten, exposure to cow's milk during infancy and/or childhood, and short duration of breast- feeding; 3. Lower intake of serum 25 hydroxyvitamin D in early infancy, vitamin E, anti-oxidants (e.g., carotenoids, ascorbic acid, selenium, or omega-3 fatty acids); 4. Higher frequency of specific (e.g., enterovirus, rotavirus, or bacterial) infections, or non-specific childhood infections including those that exhibit molecular mimicry; 5. Increased exposure to routine childhood immunizations and their timing; 6. Environmental factors that may be contained in drinking water (e.g., low concentrations of zinc or high concentrations of nitrates, or lower pH levels); 7. Exposure to household pets, and various allergies; 8. Excessive weight gain; 9. Increased psychological stress. 2. The risk of persistent beta-cell autoimmunity is lower in children from the general population than in offspring or siblings of T1DM patients when stratifying for the HLA DR-DQ genotype and exposure to environmental triggers. 3. The interaction of HLA DR-DQ genotype with exposure to dietary or infectious factors leads to increased incidence of beta-cell autoimmunity and T1DM. 4. We expect that in some families study participation will be associated with affective (anxiety, depression) and behavioral responses (e.g. actions to prevent possible T1DM).
Trial information was received from ClinicalTrials.gov and was last updated in December 2016.
Information provided to ClinicalTrials.gov by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).